Skip to main content

Nicolás Miguel Fissolo

I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Investigador/a postdoctoral
Multiple Sclerosis Centre of Catalonia

Nicolás Miguel Fissolo

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Investigador/a postdoctoral
Multiple Sclerosis Centre of Catalonia

I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease.

I graduated as a biochemist in 1999 from the University of Córdoba (Argentina). In 2005 I obtained a PhD in human biology from the University of Ulm (Germany) for my work in the DNA vaccine field. Afterwards, I carried out a 3-year postdoctoral stay at the Hertie Institut for Brain Research at the University of Tübingen (Germany) focused on the study of antigenic presentation in multiple sclerosis. In 2008 I joined the research group of the clinical neuroimmunology - Cemcat directed by Dr. Xavier Montalban where I have been working until now.

Since 2010 I have been working as principal investigator of several projects focused on the identification of new molecular biomarkers that allow the characterization of the different aspects of the disease, among which are included prognostic biomarkers in the initial phases of the disease, biomarkers of response to treatment, and biomarkers of disease activity.

Projects

Vacunas de ADN en Esclerosis Múltiple

IP: Nicolás Miguel Fissolo
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 62315
Reference: PI10/01654
Duration: 01/01/2011 - 31/12/2014

Unitat de Neuroimmunologia Clínica (UNiC)

IP: Unitat de Neuroimmunologia Clínica (UNiC)
Collaborators: Susana Otero Romero, Carlos Nos Llopis, Unitat de Neuroimmunologia Clínica (UNiC), Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo , Georgina Arrambide García
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 793
Duration: 01/01/2010 - 30/04/2014

Vacunas de ADN en esclerosis múltiple.

IP: Vacunas de ADN en esclerosis múltiple.
Collaborators: Nicolás Miguel Fissolo
Funding agency: Fundació Institut de Recerca HUVH
Funding: 90000
Reference: POST/IR-HUVH/1/2008
Duration: 01/01/2009 - 31/12/2011

REEM - Red Española de Esclerosis Múltiple

IP: REEM - Red Española de Esclerosis Múltiple
Collaborators: Carlos Nos Llopis, REEM - Red Española de Esclerosis Múltiple, Jaume Sastre Garriga, Jordi Rio Izquierdo, Fco. Javier Aymerich Martínez, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Alex Rovira Cañellas, Mar Tintore Subirana, M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo
Funding agency: Instituto de Salud Carlos III
Funding: 364373.77
Reference: RD07/0060/0020
Duration: 01/01/2008 - 31/12/2014

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Maria Carme Dinarès Fernández

Maria Carme Dinarès Fernández

Senior researcher
Translational Molecular Pathology
Read more
Pamela Torrano Soler

Pamela Torrano Soler

Gestió i Administració
Clinical Research Development Directorate
Read more
Marta Rodríguez Aliberas

Marta Rodríguez Aliberas

Postdoctoral researcher
Transfusional Medicine
Read more
Marc Patricio Liebana

Marc Patricio Liebana

Predoctoral researcher
Nephrology and kidney transplantation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.